Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats

被引:44
作者
Choi, JS
Choi, HK
Shin, SC
机构
[1] Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea
[2] Chosun Univ, Coll Pharm, Kwangju 501759, South Korea
关键词
paclitaxel; flavone; pharmacokinetics; bioavailability;
D O I
10.1016/j.ijpharm.2004.01.032
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The purpose of this study was to investigate the effect of flavone on the bioavailability of paclitaxel orally coadministered in rats. Paclitaxel (40 mg/kg) and flavone (2, 10, 20 mg/kg) were orally administered to rats orally. The plasma concentration of paclitaxel with flavone increased significantly (P < 0.01) compared to that of paclitaxel control. Area under the plasma concentration-time curve (AUC) of paclitaxel with the dose of 2-20mg/kg flavone was significantly (P < 0.05 at 10mg/kg, P < 0.01 at 20mg/kg) higher than that of control. AUCs of paclitaxel were increased dose-dependently in the dose range of flavone. The absorption rate constant (K-a) of paclitaxel with the dose of 10-20 mglkg flavone was significantly increased (P < 0.05 at 10 mg/kg, P < 0.01 at 20 mg/kg) compared to that of control. Peak concentration (C-max) of paclitaxel with the dose of 10-20 mg/kg flavone were significantly increased (P < 0.05 at 10 mg/kg, P < 0.01 at 20 mg/kg) compared to that of control. Half-life (t(1/2)) of paclitaxel with the dose of 10-20 mg/kg flavone was significantly prolonged (P < 0.05 at 10 mg/kg, P < 0.01 at 20 mg/kg) compared to that of control. The relative bioavailability increased significantly by about 2.38- or 3.10-fold (P < 0.05 at 10 mg/kg, P < 0.01 at 20 mg/kg) compared to that of paclitaxel control. Based on these results, It might be considered that the bioavailability of paclitaxel coadministered with flavone was significantly enhanced by the both inhibition of cytochrome P-450 and the P-gp efflux pump in the intestinal mucosa. It could be possible to administer paclitaxel orally besides the established IV route. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 30 条
[1]
Bardelmeijer HA, 2000, CLIN CANCER RES, V6, P4416
[2]
A PHASE-I TRIAL OF TAXOL GIVEN BY A 6-HOUR INTRAVENOUS-INFUSION [J].
BROWN, T ;
HAVLIN, K ;
WEISS, G ;
CAGNOLA, J ;
KOELLER, J ;
KUHN, J ;
RIZZO, J ;
CRAIG, J ;
PHILLIPS, J ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1261-1267
[3]
Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin [J].
Choi, JS ;
Jo, BW ;
Kim, YC .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 57 (02) :313-318
[4]
Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein [J].
Conseil, G ;
Baubichon-Cortay, H ;
Dayan, G ;
Jault, JM ;
Barron, D ;
Di Pietro, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (17) :9831-9836
[5]
CRESTEIL T, 1994, CANCER RES, V54, P386
[6]
Cunningham D, 1999, SEMIN ONCOL, V26, P6
[7]
HIROSHI F, 1994, JPN J CANC CHEMOTHER, V21, P659
[8]
Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450 [J].
Hodek, P ;
Trefil, P ;
Stiborová, M .
CHEMICO-BIOLOGICAL INTERACTIONS, 2002, 139 (01) :1-21
[9]
PHASE-II TRIAL OF TAXOL, AN ACTIVE-DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER [J].
HOLMES, FA ;
WALTERS, RS ;
THERIAULT, RL ;
FORMAN, AD ;
NEWTON, LK ;
RABER, MN ;
BUZDAR, AU ;
FRYE, DK ;
HORTOBAGYI, GN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (24) :1797-1805
[10]
KUMAR GN, 1994, J PHARMACOL EXP THER, V268, P1160